Guerbet announces the acquisition of a new microsphere technology to strengthen its interventional imaging range
April 26 2018 - 12:30PM
- Acquisition of a technology developed by Occlugel, a French
company specialized in the R&D of microspheres used in
embolization;
- This new technology will round out Guerbet's Interventional
Imaging solutions and create synergies with the Accurate range of
anti-reflux microcatheters.
Villepinte (France), April 26, 2018 (18:00
CEST) - Guerbet (FR0000032526 GBT), a global specialist in
contrast agents and solutions for medical imaging, announced today
that it has signed an agreement to acquire a laboratory-stage
technology developed by Occlugel, a French company specialized in
the R&D of microspheres used in embolization.
This acquisition is line with the GEAR 2023
strategic plan, and is one of two acquisitions planned by the end
of this financial year.
"We are very pleased to integrate this new
microsphere technology into our Interventional Imaging R&D
program", said Claire Corot, Research, Innovation & Business
Development VP.
Under the terms of the agreement and in exchange
for the acquisition of this technology, Guerbet has made an initial
payment of €3 million, with additional payments conditional on
completing the technology transfer and achieving regulatory
objectives.
A complementary technology for Interventional Imaging
The technology will be used in several ranges of
microspheres for vascular embolization of benign tumors, for
example uterine fibroma and prostate adenoma, and for vascular
chemoembolization of malignant tumors, including in some liver,
lung and kidney cancers.
This technology will complete the existing range
of Guerbet's Interventional Imaging solutions, and above all create
strong synergies with the Accurate range of anti-reflux
microcatheters, acquired recently by Guerbet.
About Guerbet
Guerbet is a pioneer in the contrast-agent
field, with more than 90 years' experience, and is a leader in
medical imaging worldwide. It offers a comprehensive range of
pharmaceutical products, medical devices and services for
diagnostic and interventional imaging, to improve the diagnosis and
treatment of patients. With 7% of revenue dedicated to R&D and
more than 200 employees distributed amongst its three centers in
France and the United States, Guerbet is a substantial investor in
research and innovation. Guerbet (GBT) is listed on Euronext Paris
(segment B - mid caps) and generated €807 million in revenue in
2017. For more information about Guerbet, please visit
www.guerbet.com
Media Relations
Guerbet Global Alize RP Caroline
Carmagnol and Wendy Rigal
+33 (0)1 44 54 36 66 /
+33 (0)6 48 82 18 94
guerbet@alizerp.com |
|
Guerbet (EU:GBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Oct 2023 to Oct 2024